Form 4: Apogee CMO Sells Shares After Option Exercise

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), reported transactions on February 4, 2026.
• Dambkowski acquired 4,125 shares of common stock by exercising stock options at a price of $22.86 per share.
• Concurrently, Dambkowski disposed of a total of 5,500 shares of common stock through multiple sales transactions.
• The sales were executed at weighted average prices ranging from $64.88 to $68.94 per share.
• All reported sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
• Following these transactions, Dambkowski beneficially owns 211,148 shares of common stock directly.
• Dambkowski also holds 135,415 derivative securities (stock options) with an exercise price of $22.86, which will vest in monthly installments through December 18, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves insider selling, the transactions were pre-planned under a Rule 10b5-1 plan, which mitigates concerns about the timing or motivation behind the sales. The significant profit realized by the officer reflects positively on the stock's performance for option holders.

Positives

• The Chief Medical Officer realized a significant profit by exercising options at $22.86 and selling shares at prices ranging from $64.88 to $68.94, indicating a substantial increase in the company's stock value since the options were granted.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to personal financial management rather than a reaction to new, undisclosed negative information about the company.

Negatives

• The net effect of the transactions is a reduction in the Chief Medical Officer's direct common stock holdings by 1,375 shares (4,125 acquired 5,500 disposed), which could be perceived as a slight decrease in insider alignment, although the overall holding remains substantial.

Future Outlook

This filing is a transactional report and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 trading plans, are a routine part of executive compensation and personal financial management. Such planned sales are generally viewed as less indicative of management's sentiment about the company's future prospects compared to unplanned, open-market transactions. The significant spread between the option exercise price and the sale price highlights the value creation for the executive through their compensation package.

Stakeholder Impact

• Shareholders: May observe a slight reduction in direct insider ownership, but the pre-planned nature of the sales under Rule 10b5-1 typically minimizes negative sentiment. The profit realized by the CMO could be seen as a positive indicator of past stock performance.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

A single Form 4 filing detailing pre-planned insider transactions, especially an exercise and sale, typically does not provide sufficient new fundamental information to warrant a change in investment recommendation. The transactions are routine and reflect personal financial planning rather than a shift in the company's operational outlook. Investors should continue to evaluate Apogee Therapeutics based on its core business performance, financial results, and strategic developments.

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Trading, Stock Options, Share Sale, Carl Dambkowski, Chief Medical Officer, Rule 10b5-1 Plan